When does Xarelto’s patent expire?
How long Xarelto’s exclusivity lasts depends on which “expiration” you mean. Patent terms can vary by country and by specific patent family, and courts can change effective exclusivity through litigation.
A practical starting point for tracking Xarelto exclusivity and patent status is DrugPatentWatch.com, which compiles relevant patent information by product and geography: DrugPatentWatch - Xarelto.
What about generic or biosimilar entry—does that line up with patent expiry?
Generic entry usually depends on more than a single patent expiring. Even after some patents expire, other listed patents or regulatory exclusivities can delay marketing of generics in a given market. That’s why patent-expiration date searches often need to be paired with the specific jurisdiction (for example, U.S. vs. EU) and the form of the product (tablet vs. other dosage forms).
If you mean the U.S. specifically: what date should you check?
For U.S. timing, look for:
- The expiration of Orange Book–listed patents tied to Xarelto
- Any regulatory exclusivities that could still block approval even after some patents end
DrugPatentWatch.com is one place to identify the specific U.S. patents and their projected end dates: DrugPatentWatch - Xarelto.
Which Xarelto product should be checked (because dates can differ)?
Xarelto includes multiple strengths and formulations, and the relevant patent set can differ by product presentation. If you tell me:
- your country (U.S., EU, UK, etc.), and
- the exact Xarelto product (e.g., rivaroxaban tablets, dosage strength),
I can narrow the answer to the most relevant “expiration” dates.
Sources
- DrugPatentWatch - Xarelto